EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications

Maaike Y Kapteijn iD, Nina Bakker, Johan A F Koekkoek, Henri H Versteeg, Jeroen T Buijs iD

Thrombosis and Haemostasis · 2025-05 · 125 (05) · 421-434

DOI: 10.1055/s-0044-1789592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 21.08.2024. Verfasst von Maaike Y Kapteijn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with glioblastoma are among the cancer patients with the highest risk of developing venous thromboembolism (VTE). Long-term thromboprophylaxis is not generally prescribed because of the increased susceptibility of glioblastoma patients to intracranial hemorrhage. This review provides an overview of the current clinical standard for glioblastoma patients, as well as the molecular and genetic background which underlies the high incidence of VTE. The two main procoagulant proteins involved in glioblastoma-related VTE, podoplanin and tissue factor, are described, in addition to the genetic aberrations that can be linked to a hypercoagulable state in glioblastoma. Furthermore, possible novel biomarkers and future treatment strategies are discussed, along with the potential of sequencing approaches toward personalized risk prediction for VTE. A glioblastoma-specific VTE risk stratification model may help identifying those patients in which the increased risk of bleeding due to extended anticoagulation is outweighed by the decreased risk of VTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismGlioblastomaBrain NeoplasmsHumansRisk FactorsAnticoagulantsBlood CoagulationThromboplastinRisk AssessmentGenetic Predisposition to DiseasePodoplanin

Substanzen

AnticoagulantsPDPN protein, humanThromboplastinPodoplanin

Autor:innen und Institutionen

  • Division of Thrombosis and Hemostasis, Department of Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.

ORCID-Profile: Maaike Y Kapteijn, Jeroen T Buijs

Zitieren

APA

Kapteijn, M. Y., Bakker, N., Koekkoek, J. A. F., Versteeg, H. H., & Buijs, J. T. (2025). Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications. Thrombosis and Haemostasis, 125(05), 421-434. https://doi.org/10.1055/s-0044-1789592

Vancouver

Kapteijn MY, Bakker N, Koekkoek JAF, Versteeg HH, Buijs JT. Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications. Thrombosis and Haemostasis. 2025;125(05):421-434. doi:10.1055/s-0044-1789592

BibTeX
@article{Kapteijn2025,
  author = {Kapteijn, Maaike Y and Bakker, Nina and Koekkoek, Johan A F and Versteeg, Henri H and Buijs, Jeroen T},
  title = {Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {05},
  pages = {421--434},
  doi = {10.1055/s-0044-1789592}
}
Kostenlos starten →